HUMAN VACCINES & IMMUNOTHERAPEUTICS 2017, VOL. 13, NO. 4, 740 http://dx.doi.org/10.1080/21645515.2017.1294955
InterveXion Therapeutics Misty Stevens Operations Director, InterveXion Therapeutics, LLC, Little Rock, AR, USA 1) How and when did your company start, and where are you located? InterveXion Therapeutics was founded in 2004, based on technology discovered at and licensed from the University of Arkansas for Medical Sciences. We are located in Little Rock, Arkansas. 2) How many employees do you have, and how do you ﬁnd and attract them? We are a small virtual team consisting primarily of our key founding scientists. 3) What are the main focus and platform technology(ies) of your company? Our main focus is on the development of therapeutic agents that neutralize toxins in the body, such as drugs of abuse. Our platform technology is based on using high-afﬁnity antibodies and vaccines to drugs of abuse to sequester them away from their sites of action in the brain. 4) Can you provide a short overview of your product pipeline? Our lead product is a monoclonal antibody against methamphetamine which has completed Phase 1 clinical safety evaluation (IXT-m200) and is preparing for Phase 2 studies. Our most advanced follow-on prorgram is a vaccine against methamphetamine which is currently in late preclinical development. 5) Who is your competition, and what advantage(s) do your products / technology offer? We believe that our products are highly unique in the industry. By providing pharmacokinetic, rather than pharmacodynamic, antagonism, we circumvent classic problems of treatment of drug addiction and its complex biochemical and behavioral challenges. 6) What were the “highlights“ in your recent product development? We have recently been awarded “Fast Track” status for our methamphetamine antibody by the US FDA.
CONTACT Misty Stevens [email protected]
7) What have been the most critical problems in developing products in your ﬁeld, and how can your company’s technology help overcome these problems? Most treatments for drug addiction rely on intervening in some way with the way the drugs work in the brain. We reduce the ability of the drug to get to the brain in the ﬁrst place – a very different approach. 8) What is your company’s value proposition? We believe our platform of pharmacokinetic antagonism is our most important value proposition, as well as our small, ﬂexible expert team of scientists advancing our programs. 9) What business development strategy do you pursue? We are actively interested in securing a development partner for our assets to facilitate our ability to rapidly advance our programs into the clinic. 10) How does your company attract partners? We network extensively in the biotech space to identify relevant and interested potential partners. 11) Who are your most important partners? Our assets are unpartnered at this time. 12) How do you balance performing work in-house vs outsourcing? As a virtual company almost all of our work is conducted via outsourcing. 13) What are your product development goals for the next 3 years? We intend to continue to advance IXT-m200 through clinical development, and move our vaccine program into clinical development. For more information visit http://intervexion.com/
4301 W. Markham St. #831, Little Rock, AR 72205, USA.
© 2017 Misty Stevens. Published with license by Taylor & Francis. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.